Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Division of Nephrology, Washington University School of Medicine, St. Louis, Missouri.
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):251-261. doi: 10.2215/CJN.10960720. Epub 2021 Jan 15.
Kidneys from hepatitis C virus (HCV) viremic donors have become more commonly accepted for transplant, especially after effective direct-acting antiviral therapy became available in 2014. We examined the contemporary trend of kidney discard from donors with HCV seropositivity and viremia.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from the Organ Procurement and Transplantation Network were used to identify deceased donor kidneys recovered for transplant. The exposure was donor HCV antibody status in the first analyses, and donor HCV antibody and viremia status in the second analyses. Multilevel, multivariable logistic regression was used to assess the association of these HCV exposure measures with kidney discard, adjusted for donor characteristics. Multilevel analyses were conducted to account for similar kidney discard pattern within clusters of organ procurement organizations and regions.
Among 225,479 kidneys recovered from 2005 to 2019, 5% were from HCV seropositive donors. Compared with HCV seronegative kidneys, the odds of HCV seropositive kidney discard gradually declined, from a multivariable-adjusted odds ratio (aOR) of 7.06 (95% confidence interval [95% CI], 5.65 to 8.81) in 2014, to 1.20 (95% CI, 1.02 to 1.42) in 2019. Among 82,090 kidneys with nucleic acid amplification test results in 2015-2019, 4% were from HCV viremic donors and 2% were from aviremic seropositive donors. Compared with HCV aviremic seronegative kidneys, the odds of HCV viremic kidney discard decreased from an aOR of 4.89 (95% CI, 4.03 to 5.92) in 2018, to 1.48 (95% CI, 1.22 to 1.81) in 2019. By 2018 and 2019, aviremic seropositive status was not associated with higher odds of discard (2018: aOR, 1.13; 95% CI, 0.88 to 1.45; and 2019: aOR, 0.97; 95% CI, 0.76 to 1.23).
Despite the decrease in kidney discard in recent years, kidneys from viremic (compared with aviremic seronegative) donors still had 48% higher odds of discard in 2019. The potential of these discarded organs to provide successful transplantation should be explored.
自 2014 年有效直接作用抗病毒疗法问世以来,丙型肝炎病毒(HCV)病毒血症供体的肾脏越来越多地被接受用于移植,尤其是在 HCV 病毒血症供体的肾脏越来越多地被接受用于移植之后。我们研究了 HCV 血清阳性和病毒血症供体肾脏丢弃的当代趋势。
设计、地点、参与者和测量方法:利用器官获取和移植网络的数据确定用于移植的已故供体肾脏。在第一分析中,暴露于供体 HCV 抗体状态,在第二分析中,暴露于供体 HCV 抗体和病毒血症状态。使用多水平多变量逻辑回归来评估这些 HCV 暴露指标与肾脏丢弃的相关性,同时调整供体特征。进行多水平分析以解释器官获取组织和地区集群内相似的肾脏丢弃模式。
在 2005 年至 2019 年期间恢复的 225479 个肾脏中,有 5%来自 HCV 血清阳性供体。与 HCV 血清阴性肾脏相比,HCV 血清阳性肾脏丢弃的几率逐渐降低,多变量调整后的优势比(aOR)从 2014 年的 7.06(95%置信区间[95%CI],5.65 至 8.81)降至 2019 年的 1.20(95%CI,1.02 至 1.42)。在 2015 年至 2019 年有核酸扩增试验结果的 82090 个肾脏中,有 4%来自 HCV 病毒血症供体,有 2%来自 HCV 血清阳性但无病毒血症供体。与 HCV 无病毒血症血清阴性肾脏相比,HCV 病毒血症肾脏丢弃的几率从 2018 年的 aOR 4.89(95%CI,4.03 至 5.92)降至 2019 年的 1.48(95%CI,1.22 至 1.81)。到 2018 年和 2019 年,无病毒血症血清阳性状态与更高的丢弃几率无关(2018 年:aOR,1.13;95%CI,0.88 至 1.45;2019 年:aOR,0.97;95%CI,0.76 至 1.23)。
尽管近年来肾脏丢弃率有所下降,但在 2019 年,来自病毒血症(与无病毒血症血清阴性)供体的肾脏仍然有 48%更高的丢弃几率。这些被丢弃的器官具有成功移植的潜力,应予以探索。